Skip to content

VCTs – Time to diversify

By Oliver Warren, Investor Relations Associate Since April 6 last year, £580m has been invested in VCTs, a record amount at this stage and a more than impressive show of confidence in the UK’s early-stage ecosystem during a period of considerable upheaval. With investors looking to alternative asset classes like venture capital for returns, pension … Continued

The con artist ‘lawyer’ who faked his way to the top – and duped the world

The story behind Wonderhood’s new documentary featured in The Telegraph. He is known as the ‘Devil’s Advocate’, and rarely can there have been a more deliciously appropriate epithet. In a legal career that seemingly knew no bounds, Giovanni di Stefano claimed to have offered counsel to Osama bin Laden, Saddam Hussein, Slobodan Milošević, Arkan, Robert … Continued

Arecor commences US Phase 1 clinical trial of ultra-rapid insulin in combination with an insulin pump

Arecor’s AT247 has the opportunity to revolutionise diabetic management through creating in effect an artificial pancreas through a closed loop system Over 500 million people suffer with diabetes worldwide and AT247 has the potential to make both management easier and improve average blood glucose levels Arecor Therapeutics plc, the biopharmaceutical group advancing today’s therapies to … Continued

CEO Quarterly Blog

Welcome to our final quarterly update of 2021. This has been a record-breaking year for Calculus as we have delivered 11 exits and over £50million back to our investors.  Whilst Calculus’s origins are as a generalist investor, a few years ago we refined our investment strategy to focus on the fastest growing sectors in the UK – … Continued

Venture Capital – Earning its place in a multi asset portfolio

By Matthew Moynes, Assistant Director of Investor Relations, Calculus Capital Synonymous with UK venture capital investing is the attractive tax incentives provided by  HMRC which help stimulate the flow of investor capital into this important asset class. This effective risk mitigation tool can often mean the integrity of the EIS and VCT investment structure can … Continued

Scancell: As Covid mutates, the vaccine makers are adapting too

Scancell featured in the Guardian Focus on the exciting potential of T-cell immunity is spurring the sector on to create a new generation of jabs The speed at which scientists worked to develop the first Covid jabs was unprecedented. Just nine months after the UK went into lockdown, 90-year-old Margaret Keenan officially became the first person in … Continued

Genedrive’s rapid point of care COV19 testing kit receives CE-IVD certification

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that further to the announcement of 29 November 2021, its rapid point of care Genedrive® COV19-ID Kit has received CE-IVD certification under the European Communities Council Directive 98/79.   The Genedrive® COV19-ID kit is a rapid molecular diagnostic test that delivers positive results as quickly as 7.5 minutes and negative results at 17 minutes.  In … Continued

Calculus invests in Hinterview

UK-based technology company Hinterview has today announced that it has raised £3m in Series A funding. The award-winning video platform for the recruitment sector has experienced soaring demand for their technology, with growth continuing this year as the recruitment industry bounces back in a new era of hybrid-first working. This Series A round, led by … Continued

Scancell: Phase 2 clinical trial of lead immunotherapy product commences

First patient dosed in SCIB1 Phase 2 clinical trial Trial to assess whether the addition of SCIB1 to pembrolizumab (Keytruda®) will result in an improvement in the tumour response rate and overall survival in patients with advanced melanoma Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious … Continued

Spectral MD announce early results from clinical study

Accuracies of 92% and 88% in detection of severe thermal burn injury in adults and children, respectively Article published in Journal of Burn Care and Research on histological burn depth research LONDON, U.K. AND DALLAS, TX, U.S. Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company that develops proprietary AI algorithms and optical technology for … Continued

Blu Wireless showcase new 360° Tactical Vehicle Node

Blu Wireless have been showcasing their new 360° Tactical Vehicle Node, which enables scalable tactical connectivity between vehicles. In contrast to commercial networks, tactical 5G military networks necessitate systems which are standalone, secure, can be easily interfaced to existing tactical equipment and are resistant to single point of failure. Blu Wireless is a firm that … Continued

What is a Fund Looking for?

Interview with Richard Moore – Co Head of Investments – Calculus Capital Calculus Capital has over 20 years’ experience investing in UK growth companies. Calculus works in partnership with investee companies, usually taking a seat on the board and providing advice on a strategic level – with the aim of realising the full potential of … Continued

Calculus Capital delivers 4x return with sale of software company CloudTrade

Calculus portfolio company, CloudTrade, has been acquired by Advanced, a leading provider of business software, delivering a 4x return to Calculus investors in just over 3 years.   The CloudTrade platform, which automatically processes and interprets electronic documents, is primarily used to automate invoice handling for large companies, which saves time, improves accuracy and reduces … Continued

Wonderhood’s latest campaign for Starling Bank ‘Set Yourself Free’

Created by Calculus portfolio company Wonderhood Studios, the advert, “Set yourself free”, launches Starling’s new brand platform “Here to change”. It debuts on Channel 4 and Sky channels, with airings during shows including Gogglebox. Wonderhood’s first campaign for Starling Bank, aimed at new businesses, aired in February 2020.

Northern Trust invests in Essentia Analytics

Essentia’s software uses data analytics and behavioural finance research to help allocators and active asset managers make better decisions and improve their returns. Essentia expects to expand headcount and accelerate research and development following an investment by Northern Trust. Northern Trust (Nasdaq: NTRS) has reached an agreement to take an equity stake in Essentia Analytics, Ltd., … Continued

Oxford BioTherapeutics and Boehringer Ingelheim Partnership Advances Second Oncology Drug Candidate into the Clinic

Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and ADC-based therapies, today announced that it has received another milestone payment from Boehringer Ingelheim (BI) for the progress of a second oncology drug candidate (BI 765049), discovered during the first phase of the partnership, into the clinic. In addition to OBT’s … Continued

Arecor announces positive results from Phase 1 Trial of insulin product for diabetes patients

Arecor announces positive headline results from first phase 1 clinical trial of AT278 ultra-rapid acting insulin candidate for diabetes. AT278 delivers significantly accelerated PK/PD profile compared to Novorapid Potential to be first concentrated (500U/mL) ultra-rapid acting insulin product enabling miniaturisation of next generation insulin delivery devices. Potential to enable more effective disease management for insulin … Continued

Calculus strengthens Investor Relations team

Calculus is delighted to announce the appointments of Matthew Moynes and Frank Spurway as Investor Relations Assistant Director and Analyst respectively. Matthew joins Calculus from Barclays Wealth where he was the Head of Venture Capital Products responsible for managing the tax efficient third-party manager panel and driving distribution through product specialist support to Wealth Managers … Continued

Calculus’ 22nd EIS Fund open for subscription

Calculus EIS Fund was the first approved EIS Fund on the market 22nd iteration of the Fund launched this week The last 18 months have seen 10 exits across the EIS Funds including 6x return for ActiveOps Calculus Capital are delighted to launch the Calculus EIS Fund offering an opportunity to invest in entrepreneurial businesses … Continued

Arecor Announce US Phase 1 Trial

Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces U.S. Food and Drug Administration (FDA) clearance of the Group’s Investigational New Drug (IND) application for AT247, the Group’s proprietary wholly owned ultra-rapid insulin for the treatment of diabetes. The IND supports a Phase I clinical trial in … Continued

Could Scancell create the first ‘universal’ vaccine for Covid?

Approval granted for clinical trial in South Africa Vaccine targets the core of the virus, not just the spike protein eliciting a t-cell response which can destroy cells infected with any SARS CoV-2 variants and other SARS-CoV viruses that may emerge in the future. Scancell, the developer of novel immunotherapies for the treatment of cancer … Continued

Calculus Invests in Brouhaha Entertainment

Brouhaha Entertainment was founded by experienced producers: Oscar nominated Gabrielle Tana, Independent film industry pioneer Troy Lum and producer Andrew Mason Founders have successfully produced 27 films and 9 television projects to date, featuring top talent from around the globe Investment will be used to expand the team and fund development in film and particularly … Continued

Calculus exits Mologic – generating up to a 3.6x return for investors

Calculus successfully exit Mologic by sale to new philanthropic entity Global Access Health London 19 July 2021: Calculus Capital (“Calculus”), pioneers of the tax efficient investment industry, is pleased to announce the successful sale of Mologic Limited (“Mologic” or “the Company”), a world leading innovator in lateral flow and rapid diagnostic technologies, and founder of … Continued